CpG DNA vaccine adjuvant ISS 1018 CpG ODN vaccine adjuvant ISS-1018 https://www.cancer.gov/publications/dictionaries/cancer-drug/def/iss-1018-cpg-oligodeoxynucleotide ISS 1018 is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity. ISS 1018 signals through Toll-like receptor 9 (TLR9) to induce the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin-12 (IL-12), and tumor necrosis factor - alpha (TNF-alpha) by plasmacytoid dendritic cells (pDC). ISS 1018 CpG ODN promotes antigen presentation and co-stimulatory molecule expression. ISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults. It is also being investigated in combination with rituximab for treatment of b-cell or non-hodgkin's lymphoma. Oliver He, Kallan Roan ISS 1018 CpG ODN DrugBank Accession number: DB05463 ISS 1018 CpG oligodeoxynucleotide https://www.drugbank.ca/drugs/DB05463 A CpG DNA vaccine adjuvant that is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity.